Clinical Trials Sponsored by Tamir Biotechnology, Inc.

Total 254 results

ImStem Biotechnology
Rho, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States
GlaxoSmithKline
Vir Biotechnology, Inc.

Terminated

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 (COMET-PACE)

COVID-19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)

Covid19

United States, Canada, Italy, Korea, Republic of, Spain
Lixte Biotechnology Holdings, Inc.

Unknown

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Blue Lake Biotechnology Inc.

Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Recruiting

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) (COSMIC)

Covid19

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Terminated

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Covid19

United States, France, Ukraine
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)

Covid19

United States, Canada, Spain, Austria, Brazil, Peru, United Kingdom
Lixte Biotechnology Holdings, Inc.

Completed

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Neoplasms | Cancer | Tumors

United States
Blue Lake Biotechnology Inc.

Completed

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections

United States
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Covid19

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer

United States
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Breast Cancer

United States, Canada, Puerto Rico, Italy, Spain
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Lymphoma, T-Cell | T-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Sarcoma | Cervical Cancer | NSCLC | Solid Tumor, Adult

China
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Hebei Senlang Biotechnology Inc., Ltd.

Unknown

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Shanghai Longyao Biotechnology Inc., Ltd.

Unknown

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL) | Safety and Efficacy of CD19 UCAR-T Cells

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

T-lymphoblastic Lymphoma | T-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Universal CAR-γδT Cell Injection in the AML Patients

AML

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Glioblastoma Multiforme, Adult

China
Shanghai Longyao Biotechnology Inc., Ltd.

Recruiting

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells

Leukemia, T Cell

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Lymphoma, T-Cell

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

AML

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Charsire Biotechnology Corp.
ASKLEP Inc.

Completed

CSTC1 for Diabetic Foot Ulcers Phase II Study

Diabetes Mellitus | Diabetic Foot Ulcer | Wounds

Taiwan
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Completed

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, New Zealand, Thailand
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Adult B Acute Lymphoblastic Leukemia

China
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Gilead Sciences
Vir Biotechnology, Inc.

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Hong Kong, Korea, Republic of, Denmark, Australia, Thailand, Singapore, United Kingdom, New Zealand
Hebei Senlang Biotechnology Inc., Ltd.

Active, not recruiting

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Shanghai Longyao Biotechnology Inc., Ltd.

Unknown

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Relapsed and Refractory B Cell Lymphoma

China
Orthomedico Inc.
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED

Completed

The Effect of Oral Hyaluronic Acid (UltraHA®) on the Knee Function

Healthy Japanese Subjects

Japan
Massachusetts General Hospital
Puma Biotechnology, Inc.; Celcuity, Inc.

Withdrawn

Fulvestrant + Neratinib In Breast Cancer (HER2-Signal)

Metastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast Cancer

United States
Oncolys BioPharma Inc
Medigen Biotechnology Corporation

Unknown

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Taiwan, Korea, Republic of
Virginia Commonwealth University
Puma Biotechnology, Inc.

Recruiting

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Solid Tumor, Adult

United States
Brii Biosciences Limited
Vir Biotechnology, Inc.

Active, not recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection

Singapore, Thailand, Australia, China, Korea, Republic of
TaiGen Biotechnology Co., Ltd.
Quintiles, Inc.

Completed

Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia

Community-Acquired Pneumonia

Taiwan, South Africa
West Cancer Center
Puma Biotechnology, Inc.; Celcuity Inc

Active, not recruiting

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Early-stage Breast Cancer

United States
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States

Clinical Trials Sponsored by Tamir Biotechnology, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations